Interview with Beata Hauser, General Manager, Ipsen Czech Republic
Ms. Hauser, you represent what is perhaps the last major generation of medical doctors in this country that left the medical field to join the pharmaceutical business. What do you…
Ipsen is a French biopharmaceutical group dedicated to improving lives through innovative medicines in oncology, neuroscience, and rare diseases. The company also has a well-established Consumer Healthcare business.
Ms. Hauser, you represent what is perhaps the last major generation of medical doctors in this country that left the medical field to join the pharmaceutical business. What do you…
France is considered among the leading rare disease markets worldwide, both scientifically and organisationally. The country has cultivated a fully-fledged supporting ecosystem for rare conditions that is today regarded as…
Ipsen France is navigating a pivotal moment. The affiliate sits at the intersection of global pipeline expansion, rising expectations for access and renewed national ambition around industrial sovereignty and innovation.…
While China may be grappling with an economic slowdown and escalating geopolitical tensions, it remains the world’s second largest pharma market and a country that boasts an extraordinarily dynamic life…
At the 13th annual meeting of French life sciences think tank, G5 Santé – which represents the leaders of eight major French health and life sciences companies, including bioMérieux, Sanofi,…
A roundup of some of the biggest China pharma industry stories, including the progress of the US Biosecure Act targeting Chinese biotechs; Innovent’s obesity and type 2 diabetes contender’s positive…
General manager Guillaume Delmotte explores Ipsen’s strategic initiatives in China, highlighting the importance of innovation, addressing healthcare challenges, and fostering a sustainable, people-centric organization. Delmotte emphasizes the rapid pace of…
After offloading its consumer healthcare division in 2022 and in view of the gradual erosion of its top seller, Somatuline, Ipsen opted to aggressively seek external assets to enrich its…
With revenues projected to reach USD 27.01 billion in 2024, France’s pharma market is ranked fifth globally. Home to a number of well-established local pharma players and a sought-after destination…
France’s life sciences industry is falling behind its European neighbours, its growth deeply hampered, the French life sciences think tank G5 Santé claims, by abusive paybacks. While the government has…
After 15 years of economic struggles coupled with political swings to the left and right, Greece seems to be on its surest footing in decades. Indeed, the Economist observed that…
Greece is a middling performer in terms of clinical trial numbers on the European stage, nestled next to Finland and Romania on total trial numbers between 2002 and 2020 but…
Ipsen’s George Carystinos explains what brought him back to Greece for a first country manager position after a succession of global roles, how the company’s global specialty care transformation is…
See our Cookie Privacy Policy Here
